DelSiTech and Tolmar announce global license and development agreement
Betsy Goodfellow | February 13, 2024 | News story | Medical Communications | DelSiTech, Pharmacy, Tolmar, collaboration
DelSiTech and Tolmar International have announced that they have entered into a global license and development agreement, following a previous investment from Tolmar in January 2024.
Under the terms of this agreement, Tolmar will gain the global license to utilise DelSiTech’s proprietary, silica-based drug delivery technology platform for the development and commercialisation of two currently undisclosed injectable drug compounds. Both companies are expected to collaborated for further development opportunities using controlled release drug products based on Silica Matrix, for various therapeutic areas including urology, reproductive health and paediatric endocrinology.
DelSiTech will be eligible to receive an upfront payment, as well as development and commercial milestone payments and royalties on net sales of licensed products, although no amounts have as yet been disclosed.
Lasse Leino, chief executive officer at DelSiTech, commented: “We are thrilled to expand our partnership with Tolmar, which further validates the potential of our proprietary, silica-based, drug delivery technology platform. By joining forces and combining our expertise in advanced drug delivery technologies, we have the ability and potential to develop novel products for the benefit of patients in need of improved therapies. The licensing agreement is a natural next step, following investment from Tolmar at the beginning of this year.”
Betsy Goodfellow
Related Content
EVerZom enters research and licensing agreement with GENFIT
EVerZom, a French biotech company developing exosome-based therapies for regenerative medicine, has entered into a …
Custom Pharmaceuticals launches new company for drug product development
Customs Pharmaceuticals, a full-service contract development and manufacturing organisation (CDMO), has launched Centrix Pharma Solutions, …
AAX Biotech announces collaboration for cardiovascular antibody therapy
Swedish biotech firm AAX Biotech has entered a new collaboration focused on the development of …
